AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02089594
Drug: Hyperbaric Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
Trial: NCT02089594
Drug: No Hyperbaric Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
Trial: NCT02085694
Drug: Lactobacillus brevis CD2
RxNorm normalized name: lactobacillus brevis CD2
DrugBank: Lactobacillus brevis (DB18532)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01062152
Drug: Ezatiostat Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
Trial: NCT02455362
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
Trial: NCT01810380
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-4 mg/day, once daily, tablets, orally
Trial: NCT01810380
Drug: Quetiapine extended release
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400-800 mg/day, once daily, encapsulated tablets, orally
Trial: NCT03290794
Drug: Aflibercept (Eylea, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Aflibercept as prescribed by the treating Physician
Trial: NCT01062152
Drug: Lenalidomide (Revlimid®)
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
Trial: NCT01908478
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01908478
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01212757
Drug: Apremilast 20mg
RxNorm normalized name: APREMILAST 20MG ORAL TAB
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 20 mg twice daily, orally
Trial: NCT01212757
Drug: Apremilast 30mg
RxNorm normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 30 mg twice daily, orally
Trial: NCT01212757
Drug: Placebo + 20 mg Apremilast
RxNorm normalized name: apremilast 20 MG
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo + 20 mg Apremilast
Trial: NCT01212757
Drug: Placebo + 30 mg Apremilast
RxNorm normalized name: apremilast 30 MG
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo + 30 mg Apremilast
Trial: NCT01603212
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I.
Trial: NCT01057186
Drug: Sevelamer
RxNorm normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pills. Individual dosage depending on clinical symptoms/phenotype.
Trial: NCT01442714
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
Trial: NCT01603212
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.
Trial: NCT01603212
Drug: Interferon Alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
Trial: NCT04587479
Drug: JAB-8263
RxNorm normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable dose, orally Q2D with 28 days each cycle
Trial: NCT01442714
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
Trial: NCT01441804
Drug: Peginterferon alfa2a
RxNorm normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Trial: NCT01441804
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
Trial: NCT00307814
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03594461
Drug: Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
Trial: NCT01441804
Drug: Peginterferon alfa2a
RxNorm normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
Trial: NCT01441804
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Trial: NCT00116220
Drug: Flutamide (Eulexin) and Lupron or Zoladex
RxNorm normalized name: flutamide Oral Capsule [Eulexin]
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgen suppression therapy
Trial: NCT01537133
Drug: fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
Trial: NCT03224260
Drug: BMS-986177
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Suspension
Trial: NCT04356872
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immune check point inhibitor, 200mg, iv, d1
Trial: NCT04356872
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFO, 1.8 g/m2/d, d1-5
Trial: NCT00569946
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops.
Trial: NCT00876044
Drug: aflibercept (AVE0005)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous route
Trial: NCT04257851
Drug: Sumatriptan Succinate Oral Tablet
RxNorm normalized name: Sumatriptan Succinate
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan tablet (25 mg/12h)
Trial: NCT01796093
Drug: Digoxin and ivabradine
RxNorm normalized name: carvedilol and ivabradine
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No more details
Trial: NCT00432653
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03465488
Drug: Albendazole Pill 400mg (GSK)
RxNorm normalized name: albendazole Pill
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One single dose of 400mg Albendazole is provided at baseline.
Trial: NCT00053222
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04509401
Drug: placebo of vitamin B6 and magnesium
RxNorm normalized name: magnesium oxide / vitamin B6
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
Trial: NCT00785772
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-200mg once a day
Trial: NCT00785772
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-500mg once a day
Trial: NCT00785772
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400-1000mg (200-500 mg twice a day)
Trial: NCT03175016
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
Trial: NCT03140176
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
Trial: NCT01414231
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
Trial: NCT01204528
Drug: Zemplar
RxNorm normalized name: Zemplar
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D receptor activator (VDRA)
Trial: NCT04619914
Drug: letrozole (Femara; Novartis pharma AG, Basle, Switzerland)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Trial: NCT03667547
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir 600 mg tablet
Trial: NCT03580967
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
Trial: NCT03778593
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
Trial: NCT03778593
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
Trial: NCT03778593
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
Trial: NCT03778593
Drug: 5% dextrose water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
Trial: NCT03457636
Drug: Doxycycline Anhydrous 40 MG
RxNorm normalized name: doxycycline anhydrous 40 MG
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
Trial: NCT02932293
Drug: SOF+DCV+SMV
RxNorm normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Trial: NCT03223883
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement for 12 months
Trial: NCT03457636
Drug: Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
Trial: NCT03158090
Drug: sandostatin
RxNorm normalized name: Sandostatin
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Trial: NCT03838796
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
Trial: NCT00550290
Drug: Cefazolin PostOperatively
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
Trial: NCT02588261
Drug: naquotinib mesilate
RxNorm normalized name: mesylate
DrugBank: Naquotinib (DB12036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
Trial: NCT02588261
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
Trial: NCT02588261
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
Trial: NCT02337010
Drug: Fluid bolus
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
Trial: NCT01647893
Drug: CTB-001
RxNorm normalized name: Syn023 component ctb-011
DrugBank: CTB001 (DB18316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus or IV infusion
Trial: NCT02353715
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02353715
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02353715
Drug: Sipuleucel-T
RxNorm normalized name: Sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00550290
Drug: Cefazolin Preoperatively
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
Trial: NCT04479449
Drug: SP-8203
RxNorm normalized name: SP-8203
DrugBank: SP-8203 (DB11670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
Trial: NCT01035619
Drug: moxidectin
RxNorm normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Dose Moxidectin 4 mg
Trial: NCT02674347
Drug: 3 g or 6 g Zidebactam
RxNorm normalized name: PRED-G 0.3 % / 0.6 % Ophthalmic Ointment
DrugBank: Zidebactam (DB13090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV for over a duration of 60 minutes
Trial: NCT01499108
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
Trial: NCT00633412
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg oral daily
Trial: NCT00633412
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg oral twice daily
Trial: NCT00633412
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg oral tablet daily
Trial: NCT00766064
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline.
Trial: NCT03600870
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
Trial: NCT01749787
Drug: PRTX-100 at 1.5 mcg/kg
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749787
Drug: PRTX-100 at 3.0 mcg/kg
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749787
Drug: PRTX-100 at 6.0 mcg/kg
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749787
Drug: PRTX-100 at 12.0 mcg/kg
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749787
Drug: PRTX-100 at 240 mcg
RxNorm normalized name: AT-III
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749787
Drug: PRTX-100 at 420 mcg
RxNorm normalized name: AT-III
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no